• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

轴性脊柱关节炎:疾病概述

Axial Spondyloarthritis: an overview of the disease.

作者信息

Ivanova Mariana, Zimba Olena, Dimitrov Ivan, Angelov Alexander K, Georgiev Tsvetoslav

机构信息

Medical Faculty, Medical University-Sofia, Sofia, Bulgaria.

Clinic of Rheumatology, University Hospital "St. Ivan Rilski", 13, Urvich St., Sofia, 1612, Bulgaria.

出版信息

Rheumatol Int. 2024 Sep;44(9):1607-1619. doi: 10.1007/s00296-024-05601-9. Epub 2024 Apr 30.

DOI:10.1007/s00296-024-05601-9
PMID:38689098
Abstract

Axial Spondyloarthritis (axSpA) is a chronic, inflammatory, immune-mediated rheumatic disease that comprises two subsets, non-radiographic and radiographic axSpA, and belongs to a heterogeneous group of spondyloarthritides (SpA). Over the years, the concept of SpA has evolved significantly, as reflected in the existing classification criteria. Considerable progress has been made in understanding the genetic and immunological basis of axSpA, in studying the processes of chronic inflammation and pathological new bone formation, which are pathognomonic for the disease. As a result, new medication therapies were developed, which bring more effective ways for disease control. This review presents a brief overview of the literature related to these aspects of disease after summarising the available information on the topic that we considered relevant. Specifically, it delves into recent research illuminating the primary pathological processes of enthesitis and associated osteitis in the context of inflammation in axSpA. The exploration extends to discussion of inflammatory pathways, with a particular focus on Th1/Th17-mediated immunity and molecular signaling pathways of syndesmophyte formation. Additionally, the review sheds light on the pivotal role of cytokine dysregulation, highlighting the significance of the IL-23/17 axis and TNF-α in this intricate network of immune responses which is decisive for therapeutic approaches in the disease.

摘要

轴性脊柱关节炎(axSpA)是一种慢性、炎症性、免疫介导的风湿性疾病,它包括两个亚组,即非放射学性和放射学性axSpA,属于脊柱关节炎(SpA)这一异质性疾病组。多年来,SpA的概念已显著演变,这在现有的分类标准中有所体现。在理解axSpA的遗传和免疫学基础、研究慢性炎症和病理性新骨形成过程(这些是该疾病的特征性表现)方面已经取得了相当大的进展。因此,开发了新的药物治疗方法,为疾病控制带来了更有效的途径。在总结了我们认为相关的该主题现有信息后,本综述简要概述了与该疾病这些方面相关的文献。具体而言,它深入探讨了最近的研究,这些研究阐明了在axSpA炎症背景下附着点炎和相关骨炎的主要病理过程。探索范围扩展到对炎症途径的讨论,特别关注Th1/Th17介导的免疫和韧带骨赘形成的分子信号通路。此外,该综述揭示了细胞因子失调的关键作用,强调了IL-23/17轴和TNF-α在这个对该疾病治疗方法起决定性作用的复杂免疫反应网络中的重要性。

相似文献

1
Axial Spondyloarthritis: an overview of the disease.轴性脊柱关节炎:疾病概述
Rheumatol Int. 2024 Sep;44(9):1607-1619. doi: 10.1007/s00296-024-05601-9. Epub 2024 Apr 30.
2
Hidden in plain sight: Is there a crucial role for enthesitis assessment in the treatment and monitoring of axial spondyloarthritis?隐匿于表象之下:附着点炎评估在中轴型脊柱关节炎的治疗和监测中是否具有重要作用?
Semin Arthritis Rheum. 2021 Dec;51(6):1147-1161. doi: 10.1016/j.semarthrit.2021.07.011. Epub 2021 Jul 9.
3
Pathophysiology and immunolgical basis of axial spondyloarthritis.轴性脊柱关节炎的病理生理学和免疫学基础。
Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101897. doi: 10.1016/j.berh.2023.101897. Epub 2023 Nov 28.
4
A strategy towards disentangling treatment refractory from misdiagnosed axial Spondyloarthritis.一种用于区分治疗抵抗和误诊的中轴型 SpA 的策略。
Autoimmun Rev. 2024 Jan;23(1):103405. doi: 10.1016/j.autrev.2023.103405. Epub 2023 Aug 3.
5
Management of Axial Spondyloarthritis - Insights into Upadacitinib.中轴型脊柱关节炎的治疗——乌帕替尼的见解。
Drug Des Devel Ther. 2022 Oct 19;16:3609-3620. doi: 10.2147/DDDT.S330413. eCollection 2022.
6
No Significant Effects of IL-23 on Initiating and Perpetuating the Axial Spondyloarthritis: The Reasons for the Failure of IL-23 Inhibitors.IL-23 对起始和维持中轴型脊柱关节炎无显著影响:IL-23 抑制剂失败的原因。
Front Immunol. 2022 Feb 10;13:818413. doi: 10.3389/fimmu.2022.818413. eCollection 2022.
7
Structural disease modification in axial spondyloarthritis.中轴型脊柱关节炎的结构疾病修饰。
Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101898. doi: 10.1016/j.berh.2023.101898. Epub 2023 Dec 1.
8
Evaluation of active inflammation, chronic structural damage, and response to treatment of sacroiliitis in axial spondyloarthritis using the Spondyloarthritis research consortium of Canada scoring system.使用加拿大脊柱关节炎研究联合会评分系统评估中轴型脊柱关节炎的骶髂关节炎的活动性炎症、慢性结构损伤和治疗反应。
BMC Musculoskelet Disord. 2022 Jul 8;23(1):654. doi: 10.1186/s12891-022-05609-x.
9
Differences between radiographic and non-radiographic axial spondyloarthritis patients in a Mexican cohort.墨西哥队列中影像学和非影像学轴向脊柱关节炎患者的差异。
Sci Rep. 2024 May 6;14(1):10342. doi: 10.1038/s41598-024-61001-w.
10
Peripheral enthesitis assessed by whole-body MRI in axial spondyloarthritis: Distribution and diagnostic value.全身 MRI 评估的轴性脊柱关节炎外周附着点炎:分布及诊断价值。
Front Immunol. 2022 Aug 23;13:976800. doi: 10.3389/fimmu.2022.976800. eCollection 2022.

引用本文的文献

1
Cardiovascular risk in axial spondyloarthritis: the interplay of inflammation, traditional risk factors, and management strategies.轴性脊柱关节炎中的心血管风险:炎症、传统风险因素与管理策略的相互作用
Rheumatol Int. 2025 Sep 2;45(9):214. doi: 10.1007/s00296-025-05975-4.
2
HLA-B27 Status in Rheumatic Diseases: Clinical and Immunological Differences Between Positive and Negative Patients-A Comparative Study.风湿性疾病中的HLA - B27状态:阳性与阴性患者的临床和免疫学差异——一项比较研究
Biomedicines. 2025 Aug 16;13(8):1996. doi: 10.3390/biomedicines13081996.
3
Tailoring Inflammatory Biomarker Assessment in Axial Spondyloarthritis: A Comparative Study of Erythrocyte Sedimentation Rate and C-Reactive Protein Across Disease Profiles.

本文引用的文献

1
Pathophysiology and immunolgical basis of axial spondyloarthritis.轴性脊柱关节炎的病理生理学和免疫学基础。
Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101897. doi: 10.1016/j.berh.2023.101897. Epub 2023 Nov 28.
2
Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices.在日常临床护理中,通常不会常规区分影像学和非影像学轴向脊柱关节炎:来自风湿病诊所的真实世界数据的分析。
Rheumatol Int. 2024 Apr;44(4):653-661. doi: 10.1007/s00296-023-05463-7. Epub 2023 Oct 8.
3
Online physiotherapy for people with axial spondyloarthritis: quantitative and qualitative data from a cohort study.
强直性脊柱炎炎症生物标志物评估的个体化:不同疾病谱中红细胞沉降率和C反应蛋白的比较研究
J Pers Med. 2025 Jul 25;15(8):329. doi: 10.3390/jpm15080329.
4
Biomarkers of Inflammation and Radiographic Progression in Axial Spondyloarthritis: A Clinical Evaluation of Leptin, Adiponectin, TNF-α, and IL-17A.轴性脊柱关节炎中炎症和影像学进展的生物标志物:瘦素、脂联素、肿瘤坏死因子-α和白细胞介素-17A的临床评估
J Clin Med. 2025 Aug 7;14(15):5605. doi: 10.3390/jcm14155605.
5
The rapid detection of human HLA-B*27 gene based on BASIC isothermal detection.基于BASIC等温检测的人类HLA - B*27基因快速检测
Sci Rep. 2025 May 2;15(1):15427. doi: 10.1038/s41598-025-98642-4.
6
Early axial spondyloarthritis versus established disease: a single-center analysis based on the new ASAS definition of early disease.早期轴性脊柱关节炎与确诊疾病:基于新的ASAS早期疾病定义的单中心分析
Clin Rheumatol. 2025 Mar;44(3):1129-1134. doi: 10.1007/s10067-025-07365-4. Epub 2025 Feb 9.
7
Adhesion molecules and atherosclerosis in ankylosing spondylitis: implications for cardiovascular risk.黏附分子与强直性脊柱炎的动脉粥样硬化:心血管风险的意义。
Rheumatol Int. 2024 Oct;44(10):1837-1848. doi: 10.1007/s00296-024-05693-3. Epub 2024 Aug 24.
轴向型脊柱关节炎患者的在线物理治疗:队列研究的定量和定性数据。
Rheumatol Int. 2024 Jan;44(1):145-156. doi: 10.1007/s00296-023-05456-6. Epub 2023 Sep 21.
4
Axial Spondyloarthritis: Current Advances, Future Challenges.轴性脊柱关节炎:当前进展与未来挑战
J Rheum Dis. 2021 Apr 1;28(2):55-59. doi: 10.4078/jrd.2021.28.2.55.
5
Uncovering the Underworld of Axial Spondyloarthritis.揭开中轴型脊柱关节炎的神秘面纱。
Int J Mol Sci. 2023 Mar 30;24(7):6463. doi: 10.3390/ijms24076463.
6
Mucosal-associated invariant T cells in patients with axial spondyloarthritis.黏膜相关不变 T 细胞在中轴型脊柱关节炎患者中的作用。
Front Immunol. 2023 Mar 10;14:1128270. doi: 10.3389/fimmu.2023.1128270. eCollection 2023.
7
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.ASAS-EULAR 推荐的中轴型脊柱关节炎管理:2022 更新。
Ann Rheum Dis. 2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296. Epub 2022 Oct 21.
8
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.依奇珠单抗治疗中轴型脊柱关节炎患者的疗效和安全性:COAST 研究 2 年结果。
RMD Open. 2022 Jul;8(2). doi: 10.1136/rmdopen-2021-002165.
9
Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients.HLA-B27及疾病状态对强直性脊柱炎患者后代肠道微生物群的影响
Children (Basel). 2022 Apr 16;9(4):569. doi: 10.3390/children9040569.
10
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study.在活动性非放射性轴性脊柱关节炎患者中使用培塞利珠单抗治疗的长期安全性和临床结局:来自 3 期 C-axSpAnd 研究的 3 年结果。
RMD Open. 2022 Mar;8(1). doi: 10.1136/rmdopen-2021-002138.